Middle East & Africa Antibody Drug Conjugates Market

Middle East & Africa Antibody Drug Conjugates Market Size & Growth (2023 to 2028):

The Size of the Middle East & Africa Antibody Drug Conjugates Market was valued at USD 0.89 billion in 2022 and is estimated to reach USD 2.69 billion by 2028, to grow at a CAGR of 20.28% during the forecast period.

Antibody-drug conjugates are complex components used against cancer cells; these drugs consist of an antibody, a cytotoxic chemotherapy drug, and a linker. The increasing application of antibody-drug conjugates in oncology will bring robust growth to the MEA antibody-drug conjugate market. According to Cancer Research U.K., during 2015-2017, on average, almost 37% of new cases were reported each year in people aged 75 and over.

In addition, it is estimated that by 2035, nearly 47% of all cancer cases will occur in people aged 75 and over. Furthermore, unhealthy habits such as smoking and alcohol consumption, and lack of physical activities have increased dramatically over the past several years. As a result, cancer has been one of the most common diseases globally. The National Cancer Institute estimates that cancer diagnosis is extrapolated to approximately 19.8 million by 2025. For women, breast cancer is the most frequently diagnosed cancer in all MEA countries. In men, prostate cancer was the most commonly diagnosed cancer in MEA. Therefore, these factors could generate positive growth for the MEA antibody-drug conjugate market during the evaluation period.

Antibody-drug conjugates are the emerging new class of cancer therapy consisting of boosted monoclonal antibodies created to reach the targeting ability of monoclonal antibodies by binding to cell-killing agents. Clinical trials for many antibody-drug conjugates are underway and are expected to be approved shortly.

As a result, the market for antibody-drug conjugates may see significant growth. Furthermore, the increased cell-killing potential of monoclonal antibodies confers more excellent tumor selectivity, increasing drug tolerance and reducing systemic toxicity. The market's rapid growth can be linked to the extensive research and development activities in oncology and pharmacology related to antibody-drug conjugates. All these factors mentioned above will be responsible for the growth of the MEA antibody-drug conjugates market in years to come.

The process of manufacturing antibody-drug conjugates is a complicated, lengthy and expensive process, which requires significant capital investment and skilled operators, optimal environment, and significant operational difficulties. In addition, the unavailability of reimbursement policies in developing economies is expected to restrain the market's growth during the given forecast period.

This research report on the Middle East & Africa Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories. 

By pipeline:

• Phase
• Mode of action
  • Igg1 antibodies
  • HER2 antibodies
• Technology
• linker

By Technology:

• Seattle Genetics
• Immunogen
• Immunomedics

By End User:

• Research institutes
• Hospitals
• Clinics

By Country:

• KSA
• UAE
• Israel
• the rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Saudi Arabia Antibody drug conjugates market is anticipated to continue with a market share of 38% over the forecast period. The Middle East region dominated the global antibody-drug conjugates market. About 71% of antibody-drug conjugates are outsourced to contracted manufacturing and development organizations, complex molecules requiring cytotoxic biological and high-containment cleanroom facilities for safe handling. The increasing prevalence of cancer in the MEA region will show promising growth. Additionally, a large customer base and a well-developed research and technology sector will drive the sales numbers in Saudi Arabia, Kuwait, Qatar, and Egypt.

The UAE Antibody drug conjugates market is expected to witness moderate growth during the predicted period. In 2019, nearly 212 antibody-drug conjugates entered clinical trials, and there have been approximately 24 new antibody-drug conjugates in the past 12 months have increased at a rate of 30.5%.

The South Africa Antibody drug conjugates market is also expected to experience substantial growth between 2023 and 2028. In Southern Africa, fatality rates from cancer have increased significantly, especially prostate and cervical cancer. Therefore, there are real opportunities for companies that can provide specialized and innovative treatment options.  

KEY MARKET PLAYERS

Companies dominating the Middle East & Africa Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.,